Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 7/20 | 0.40 |
| ▸ | CA1 | P00915 | 7/20 | 0.40 |
| ▸ | CA2 | P00918 | 7/20 | 0.40 |
| ▸ | CA4 | P22748 | 3/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7138159 | 0.87 | CCR6 (0.38) | CCR6PAX8CA12CA1CA2 | |
| SCHEMBL27990536 | 0.77 | CCR6 (0.66) | CCR6PAX8CNR2KCNH2ALDH1A1 | |
| SCHEMBL25628629 | 0.76 | CCR6 (0.64) | CCR6PAX8CNR2KCNH2ALDH1A1 | |
| SCHEMBL15508590 | 0.74 | CCR6 (0.63) | CCR6PAX8CNR2KCNH2ALDH1A1 | |
| SCHEMBL28271583 | 0.73 | CCR6 (0.58) | CCR6PAX8CNR2ALDH1A1CYP3A4 | |
| SCHEMBL17275425 | 0.73 | CCR6 (0.61) | CCR6PAX8CNR2KCNH2ALDH1A1 | |
| SCHEMBL7230861 | 0.73 | ALDH1A1 (0.54) | CNR2ALOX5ALDH1A1CYP3A4TSHR | |
| SCHEMBL14476880 | 0.73 | CCR6 (0.63) | CCR6PAX8ALDH1A1CYP3A4TSHR | |
| SCHEMBL27345619 | 0.72 | CCR6 (0.56) | CCR6PAX8CNR2KCNH2ALDH1A1 | |
| SCHEMBL13661575 | 0.72 | CCR6 (0.64) | CCR6PAX8CNR2KCNH2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2003-05-15 | — | — | US | disclosed |
| US-6506733-B1 | Which process comprises hydrogenating a compound of Formula 9: presence of a catalytic amount of 20% palladium hydroxide on carbon. | AXYS PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | SERPINB1, HPN, CTRL | CCR6 2751/4885PAX8 4614/4885CA12 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.